Starpharma Holdings Limited

Starpharma Holdings' cabazitaxel is second DEP product to enter clinical stage

DEP® cabazitaxel has already delivered impressive pre-clinical results.

Picture of a laboratory
The alternative Jevtana sales are tipped to reach approximately US$500 million this year

Starpharma Holdings Limited’s (ASX:SPL) (OTCQX:SPHRY) approval to commence its phase I/II clinical trial for DEP® cabazitaxel is an important milestone.

The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® cabazitaxel.

This is central to defining a recommended phase II dose (RP2D), and then to determining anti-tumour efficacy of the product in select tumour types.

Transitions DEP® product from portfolio to clinic

The approval advances DEP® cabazitaxel, Starpharma’s second DEP® product, from its internal portfolio to the clinic.

DEP® cabazitaxel has already delivered impressive pre-clinical results showing sustained efficacy and survival benefits.

it has also eliminated neutropenia, which is a significant dose-limiting side effect of many anti-cancer drugs, including Jevtana®.

Jevtana® sales expected to reach circa US$500 million

DEP® cabazitaxel is Starpharma’s detergent-free version of cancer drug, Jevtana®, which is marketed by global pharmaceutical group Sanofi Aventis.

It is used in the treatment of advanced prostate cancer.

The drug is also under clinical development for a range of other cancer types, including testicular, ovarian, breast, bladder, and head and neck.

Jevtana® sales are estimated to reach approximately US$500 million this year.

Follows success of DEP® docetaxel

DEP® cabazitaxel is the second product from Starpharma’s DEP® platform to enter the clinic.

It follows DEP® docetaxel, which delivered positive phase I clinical results in 2017 and recently progressed to phase II.

The reproducible benefits observed for DEP® docetaxel and DEP® cabazitaxel in pre-clinical models included decreased bone marrow toxicity and enhanced efficacy.

In both cases DEP® has also allowed for a detergent-free formulation resulting in significant additional benefits for patients. 

Quick facts: Starpharma Holdings Limited

Price: $1.24

Market: ASX
Market Cap: $460.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



PFS values Infinity Lithium's flagship San José project at US$860mln

Infinity Lithium Corporation Ltd's (ASX:INF) executive director of corporate strategy Vincent Ledoux Pedailles chats to Proactive London's Andrew Scott following the publication of a PFS (pre-feasibility study) for the development of its flagship San José lithium project in Spain. The study...

26 minutes ago

2 min read